David A. Braun, MD, PhD, discusses the need for more tailored treatments that improve tumor-specific T-cell infiltration in chromophobe RCC.

David A. Braun, MD, PhD, outlines differences in the tumor biology and immune phenotypes of chromophobe and clear cell renal cell carcinoma.

Although chromophobe RCC has an immune-cold environment, ferroptosis induction may be a promising target for managing tumor resistance in this subtype.